MCID: BRN028
MIFTS: 72

Brain Cancer

Categories: Rare diseases, Cancer diseases, Neuronal diseases

Aliases & Classifications for Brain Cancer

MalaCards integrated aliases for Brain Cancer:

Name: Brain Cancer 12 55 15
Adult Brain Tumor 12 55 73
Neoplasm of Brain 12 29 6
Primary Malignant Neoplasm of Brain 12 73
Malignant Neoplasm of Brain 29 73
Brain Neoplasms 44 73
Brain Tumors 55 43
Malignant Primary Brain Neoplasm 12
Adult Malignant Brain Neoplasm 12
Malignant Tumor of Adult Brain 12
Malignant Primary Brain Tumors 55
Malignant Primary Brain Tumor 12
Malignant Tumor of Brain 12
Malignant Brain Tumour 12
Primary Brain Neoplasm 12
Brain Neoplasm, Adult 12
Brain Tumor, Primary 73
Primary Brain Tumor 12
Brain Tumor Primary 55
Tumor of the Brain 12
Brain Tumor, Adult 53
Bt - Brain Tumour 12
Brain Neoplasm 12
Cancer, Brain 40

Classifications:



Summaries for Brain Cancer

MedlinePlus : 43 A brain tumor is a growth of abnormal cells in the tissues of the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Some are primary brain tumors, which start in the brain. Others are metastatic, and they start somewhere else in the body and move to the brain. Brain tumors can cause many symptoms. Some of the most common are Headaches, often in the morning Nausea and vomiting Changes in your ability to talk, hear, or see Problems with balance or walking Problems with thinking or memory Feeling weak or sleepy Changes in your mood or behavior Seizures Doctors diagnose brain tumors by doing a neurologic exam and tests including an MRI, CT scan, and biopsy. Treatment options include watchful waiting, surgery, radiation therapy, chemotherapy, and targeted therapy. Targeted therapy uses substances that attack cancer cells without harming normal cells. Many people get a combination of treatments. NIH: National Cancer Institute

MalaCards based summary : Brain Cancer, also known as adult brain tumor, is related to supratentorial cancer and atypical teratoid rhabdoid tumor, and has symptoms including back pain, headache and pain. An important gene associated with Brain Cancer is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Endometrial cancer and Downstream signaling events of B Cell Receptor (BCR). The drugs Gliadel Wafer and Temodar have been mentioned in the context of this disorder. Affiliated tissues include brain, lung and pituitary, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain.

Wikipedia : 76 A brain tumor occurs when abnormal cells form within the brain. There are two main types of tumors:... more...

Related Diseases for Brain Cancer

Diseases related to Brain Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 218)
# Related Disease Score Top Affiliating Genes
1 supratentorial cancer 32.8 ENO2 GFAP SMARCB1 TP53
2 atypical teratoid rhabdoid tumor 32.6 GFAP SMARCB1 TP53
3 brain glioma 32.6 EGFR GFAP MGMT TP53
4 infratentorial cancer 32.4 GFAP MYCN PTCH1 SMARCB1 TP53
5 glioma susceptibility 1 31.6 IDH1 IDH2 TP53
6 anaplastic oligodendroglioma 31.3 EGFR GFAP IDH2 MGMT
7 glioma 31.2 BRAF DMBT1 EGFR IDH1 IDH2 MIR25
8 liver angiosarcoma 31.0 ENO2 NRAS TP53
9 oligodendroglioma 31.0 EGFR ENO2 GFAP IDH1 IDH2 MGMT
10 glioblastoma multiforme 30.8 DMBT1 EGFR GFAP IDH1 MGMT PIK3CA
11 lymphoma, non-hodgkin, familial 30.5 ALK BRAF NRAS PIK3CA TP53
12 thyroid cancer 30.5 BRAF NRAS PIK3CA PTCH1 PTEN TP53
13 glioblastoma 30.3 ALK BRAF DMBT1 EGFR IDH1 IDH2
14 medulloblastoma 29.6 BMI1 DMBT1 EGFR ENO2 GFAP IDH1
15 brain tumor, childhood 12.3
16 prostate cancer/brain cancer susceptibility 12.0
17 childhood germ cell brain tumor 11.9
18 adult astrocytic tumour 11.5 IDH1 IDH2 PTEN
19 interval angle-closure glaucoma 11.4 IDH1 IDH2
20 intracranial chondrosarcoma 11.4 IDH1 IDH2 TP53
21 pilocytic astrocytoma of cerebellum 11.4 BRAF IDH1 IDH2
22 gemistocytic astrocytoma 11.4 GFAP IDH2 PTEN
23 undifferentiated pleomorphic sarcoma 11.4 IDH1 IDH2 PIK3CA
24 intrahepatic cholangiocarcinoma 11.4 EGFR IDH1 IDH2 TP53
25 small cell carcinoma 11.4 EGFR ENO2 PTEN TP53
26 melanotic medulloblastoma 11.4 ENO2 GFAP SMARCB1
27 adult oligodendroglioma 11.3 IDH1 IDH2
28 brain stem cancer 11.3
29 li-fraumeni syndrome 11.3 EGFR IDH1 PTEN TP53
30 enchondroma 11.3 IDH1 IDH2
31 bile duct adenocarcinoma 11.3 IDH1 IDH2 TP53
32 basaloid squamous cell carcinoma 11.3 EGFR ENO2 TP53
33 transitional cell carcinoma 11.3 EGFR ENO2 PTEN TP53
34 cerebellopontine angle tumor 11.3 GFAP IDH1 SMARCB1
35 breast papillary carcinoma 11.3 IDH1 IDH2 PTCH1
36 protoplasmic astrocytoma 11.3 GFAP IDH2 TP53
37 thyroid hurthle cell adenoma 11.3 PIK3CA PTEN
38 brain ependymoma 11.3 EGFR TP53
39 lung benign neoplasm 11.3 EGFR ENO2 TP53
40 large cell carcinoma with rhabdoid phenotype 11.3 ENO2 SMARCB1
41 oligoastrocytoma 11.3 GFAP IDH2 MGMT
42 breast squamous cell carcinoma 11.3 EGFR PIK3CA TP53
43 acral lentiginous melanoma 11.3 BRAF NRAS PTEN
44 mixed glioma 11.3 GFAP IDH1 TP53
45 connective tissue cancer 11.3 ENO2 SMARCB1 TP53
46 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 11.3 PIK3CA PTEN TP53
47 female reproductive organ cancer 11.3 EGFR PIK3CA PTEN TP53
48 oral cavity cancer 11.3 EGFR PIK3CA PTEN TP53
49 organ system benign neoplasm 11.3 ENO2 SMARCB1 TP53
50 rhabdoid meningioma 11.3 BRAF GFAP SMARCB1

Comorbidity relations with Brain Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Brain Edema
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation Hypertension, Essential
Obstructive Hydrocephalus Schizophreniform Disorder

Graphical network of the top 20 diseases related to Brain Cancer:



Diseases related to Brain Cancer

Symptoms & Phenotypes for Brain Cancer

UMLS symptoms related to Brain Cancer:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Brain Cancer according to GeneCards Suite gene sharing:

26 (show all 34)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.16 PIK3CA EGFR
2 Decreased viability GR00221-A-1 10.16 ALK NRAS PIK3CA EGFR SMARCB1
3 Decreased viability GR00221-A-2 10.16 PIK3CA SMARCB1
4 Decreased viability GR00221-A-3 10.16 NRAS SMARCB1
5 Decreased viability GR00221-A-4 10.16 ALK PIK3CA EGFR
6 Decreased viability GR00381-A-1 10.16 SMARCB1
7 Decreased viability GR00402-S-2 10.16 ALK NRAS PIK3CA EGFR SMARCB1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.84 BRAF
9 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.84 BMI1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-116 9.84 PIK3CA
11 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.84 MYCN
12 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.84 MYCN
13 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.84 BRAF
14 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.84 PIK3CA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-16 9.84 IDH2 PIK3CA
16 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.84 BRAF PIK3CA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.84 IDH2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.84 IDH2 BMI1 MYCN BRAF PIK3CA
19 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.84 BMI1 PIK3CA
20 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.84 BRAF
21 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.84 IDH2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.84 BRAF
23 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.84 BMI1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-31 9.84 BRAF
25 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.84 BRAF
26 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.84 IDH2 PIK3CA
27 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.84 BRAF
28 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.84 PIK3CA
29 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.84 BMI1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-69 9.84 IDH2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.84 IDH2
32 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.84 BMI1
33 Decreased cell migration GR00055-A-1 9.65 EPHB2 ALK BRAF PIK3CA EGFR
34 Decreased viability in esophageal squamous lineage GR00235-A 9.65 GFAP IDH1 IDH2 MYCN BRAF DMBT1

MGI Mouse Phenotypes related to Brain Cancer:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.42 SMARCB1 PTEN PTCH1 TP53 DMBT1 BRAF
2 growth/size/body region MP:0005378 10.41 SMARCB1 PTEN PTCH1 TP53 ALK BRAF
3 behavior/neurological MP:0005386 10.4 PTCH1 SMARCB1 PTEN TP53 ALK BRAF
4 homeostasis/metabolism MP:0005376 10.39 PTCH1 SMARCB1 PTEN TP53 ALK DMBT1
5 mortality/aging MP:0010768 10.37 SMARCB1 PTEN PTCH1 TP53 ALK DMBT1
6 cardiovascular system MP:0005385 10.35 PTCH1 SMARCB1 PTEN TP53 BRAF EGFR
7 digestive/alimentary MP:0005381 10.33 SMARCB1 PTEN TP53 DMBT1 BRAF EGFR
8 embryo MP:0005380 10.28 SMARCB1 PTEN PTCH1 TP53 DMBT1 BRAF
9 immune system MP:0005387 10.28 PTEN PTCH1 SMARCB1 TP53 BRAF DMBT1
10 endocrine/exocrine gland MP:0005379 10.27 PTEN PTCH1 TP53 BRAF ALK EGFR
11 neoplasm MP:0002006 10.23 SMARCB1 PTEN TP53 ALK DMBT1 BRAF
12 nervous system MP:0003631 10.21 PTEN PTCH1 SMARCB1 TP53 BRAF ALK
13 craniofacial MP:0005382 10.2 PTCH1 TP53 BRAF EGFR ENO2 EPHB2
14 integument MP:0010771 10.13 PTEN PTCH1 TP53 BRAF ALK EGFR
15 muscle MP:0005369 10.13 PTCH1 SMARCB1 PTEN TP53 BRAF EGFR
16 liver/biliary system MP:0005370 10.05 PTEN SMARCB1 TP53 BRAF EGFR MYCN
17 hearing/vestibular/ear MP:0005377 10.03 PTCH1 TP53 BRAF DMBT1 EPHB2 EGFR
18 reproductive system MP:0005389 9.96 PTCH1 SMARCB1 PTEN TP53 BRAF ALK
19 no phenotypic analysis MP:0003012 9.95 PTCH1 TP53 EGFR MGMT NRAS MYCN
20 renal/urinary system MP:0005367 9.92 PTEN PTCH1 TP53 BRAF DMBT1 EPHB2
21 pigmentation MP:0001186 9.91 PTEN PTCH1 TP53 ALK BRAF EGFR
22 respiratory system MP:0005388 9.85 PTEN TP53 ALK BRAF EGFR ENO2
23 skeleton MP:0005390 9.65 PTEN PTCH1 TP53 BRAF ALK EGFR
24 vision/eye MP:0005391 9.4 SMARCB1 PTEN TP53 ALK BRAF EGFR

Drugs & Therapeutics for Brain Cancer

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Gliadel Wafer 18 49 CARMUSTINE Rhone-Poulenc Rorer, Guilford Pharmaceuticals February 1997
2
Temodar 18 49 TEMOZOLOMIDE Schering-Plough August 1999
3
Alecensa 18 ALECTINIB HYDROCHLORIDE Roche December 2015

Drugs for Brain Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 721)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydrocortisone Approved, Vet_approved Phase 4,Not Applicable 50-23-7 5754
2
Prednisone Approved, Vet_approved Phase 4,Phase 2 53-03-2 5865
3
Sevoflurane Approved, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 28523-86-6 5206
4
Dacarbazine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 4342-03-4 5351166
5
Temozolomide Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 85622-93-1 5394
6
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Not Applicable 113775-47-6 68602 5311068
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
8
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Not Applicable 2078-54-8 4943
9
Midazolam Approved, Illicit Phase 4,Not Applicable 59467-70-8 4192
10
Menthol Approved Phase 4,Phase 1,Phase 2,Not Applicable,Early Phase 1 2216-51-5 16666
11
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2 83-43-2 6741
12
Prednisolone Approved, Vet_approved Phase 4,Phase 2 50-24-8 5755
13
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
14 Piracetam Approved, Investigational Phase 4,Phase 2 7491-74-9
15
Clevidipine Approved, Investigational Phase 4 167221-71-8
16
Hydralazine Approved Phase 4 86-54-4 3637
17
Labetalol Approved Phase 4 36894-69-6 3869
18
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-61-6, 62-31-7 681
19
Methylphenidate Approved, Investigational Phase 4,Phase 3,Not Applicable 113-45-1 4158
20
Thrombin Approved, Investigational Phase 4
21
Bupivacaine Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 2180-92-9, 38396-39-3 2474
22
Rocuronium Approved Phase 4,Not Applicable 119302-91-9, 143558-00-3 441290
23
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 437-38-7 3345
24
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
25
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 7487-88-9 24083
26
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
27
Propranolol Approved, Investigational Phase 4 525-66-6 4946
28
Cabergoline Approved Phase 4,Phase 3,Phase 2 81409-90-7 54746
29
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 83150-76-9 383414 6400441
30
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 38916-34-6, 51110-01-1 53481605
31
Apixaban Approved Phase 4,Phase 3 503612-47-3 10182969
32
Heparin Approved, Investigational Phase 4,Phase 3,Not Applicable 9005-49-6 772 46507594
33
Warfarin Approved Phase 4 81-81-2 6691 54678486
34
Remifentanil Approved Phase 4,Phase 3,Not Applicable 132875-61-7 60815
35
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
36
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
37
Ibuprofen Approved Phase 4,Phase 3 15687-27-1 3672
38
Morphine Approved, Investigational Phase 4,Phase 2 57-27-2 5288826
39
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
40
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 120014-06-4 3152
41
Lamotrigine Approved, Investigational Phase 4,Phase 1,Phase 2 84057-84-1 3878
42
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 19982-08-2 4054
43
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2 148553-50-8 5486971
44
Topiramate Approved Phase 4,Phase 1,Phase 2 97240-79-4 5284627
45
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99-66-1 3121
46
Ephedrine Approved Phase 4 299-42-3 9294
47
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
48
Phenylephrine Approved Phase 4 59-42-7 6041
49
Pseudoephedrine Approved Phase 4 90-82-4 7028
50
Tramadol Approved, Investigational Phase 4 27203-92-5 33741

Interventional clinical trials:

(show top 50) (show all 1991)
# Name Status NCT ID Phase Drugs
1 Effect of Perioperative Glucocorticoid Replacement on Prognosis of Surgical Patients With Sellar Lesions Unknown status NCT02190994 Phase 4 Hydrocortisone;Prednisone
2 Trial of Levetiracetam in Patients With Primary Brain Tumors and Symptomatic Seizures Who Undergo Surgery Completed NCT00571155 Phase 4 levetiracetam
3 Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Completed NCT02034708 Phase 4 Dotarem®;Gadovist®/Gadavist®
4 Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
5 Surgery Versus Radiosurgery to Treat Metastatic Brain Tumors Completed NCT00075166 Phase 4
6 A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients Completed NCT00952081 Phase 4 Clevidipine
7 Multihance at 3 Tesla in Brain Tumors Completed NCT00395863 Phase 4 Multihance;Arm 2 - Magnevist
8 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
9 Phase IV Bioseal Study in Brain Tumor Surgery Completed NCT02034799 Phase 4
10 Scalp Nerve Block and Opioid Consumption in Brain Surgery Completed NCT02057367 Phase 4 Scalp block with 0.5% plain Marcaine;Scalp block with 0.9% normal saline
11 Sugammadex Given for the Reversal of Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants Completed NCT02708056 Phase 4 Sugammadex
12 The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block Completed NCT02558569 Phase 4 Levobupivacaine
13 Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
14 Dexmedetomidine and Intelligence Development in Pediatric Patients Undergoing Craniotomy Completed NCT02810899 Phase 4 dexmedetomidine;normal saline
15 Magnesium Sulphate for Attenuation of Hemodynamic Pressor Response After Myfield's Clamp Application Completed NCT03318471 Phase 4 MgSo4;0.9% NaCl
16 Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation Completed NCT00336531 Phase 4 itraconazole
17 Crossover Comparison of MultiHance and Dotarem Completed NCT02070380 Phase 4 MultiHance 0.1 mmol/kg;Dotarem;MultiHance 0.05 mmol/kg
18 Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain Completed NCT01613417 Phase 4 gadoteridol;gadobutrol
19 A Study Comparing Two Magnetic Resonance Imaging (MRI) Contrast Agents in MRI of the Brain Completed NCT00323102 Phase 4 Multihance
20 Using Propranolol in Traumatic Brain Injury to Reduce Sympathetic Storm Phenomenon Completed NCT03401515 Phase 4 Propranolol Hydrochloride 1 MG/ML
21 Validation of 3 Dimensional Laparoscopic System in Disral Pancreatectomy and Splenectomy Completed NCT02757690 Phase 4
22 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
23 Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion) Completed NCT02100228 Phase 4 Apixaban;Parenteral heparin and/or oral Vitamin K antagonist
24 Remifentanil Infusion Alone During the Closure Period for Early Emergence Following Craniotomy Completed NCT02593942 Phase 4 Remifentanil;Propofol
25 Analgesia Regimens Following Trans-sphenoidal Surgery for Pituitary Tumors Completed NCT02351700 Phase 4 IV Caldolor (IV Ibuprofen);IV Ibuprofen placebo
26 Surgical Debulking of Pituitary Adenomas Completed NCT01371643 Phase 4 Octreotide LAR
27 Light Sedation or Intubated General Anesthesia in Patients With Brain Cancer Undergoing Craniotomy Recruiting NCT02193568 Phase 4
28 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients Recruiting NCT02334722 Phase 4 Levetiracetam extended release
29 Vasopressor Effects in Anesthetized Patients Recruiting NCT02713087 Phase 4 Ephedrine;Phenylephrine
30 Single Dose Tramadol Effect on Extubation Response and Quality of Emergence Post-supratentorial Intracranial Surgery Recruiting NCT02964416 Phase 4 Injection Tramadol
31 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Recruiting NCT02478346 Phase 4 Fluorescein Sodium
32 Comparative Low and High Dose of Dexmedethomidine in Pituitary Tumor Removal by Transphenoid Approach Recruiting NCT03132259 Phase 4 high dose dexmedethomidine;low dose dexmedethomidine
33 Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions Recruiting NCT03014687 Phase 4 Placebo;Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole
34 Effect of Dexmedetomidine on Plasmatic Cortisol Response in Transsphenoidal Surgery Recruiting NCT02549768 Phase 4 Dexmedetomidine;Sodium Chloride 0.9%
35 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
36 Quality Improvement and Practice Based Research in Neurology Using the EMR Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
37 Comparison of Efficacy and Safety of the Postoperative Analgesia Methods Not yet recruiting NCT02929147 Phase 4 Morphine;Dexketoprofen;Placebo
38 Treatment of Resectable Malignant Brain Tumors Terminated NCT00415467 Phase 4
39 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Terminated NCT02028325 Phase 4 Fluorescein Sodium
40 Use of Conivaptan (Vaprisol) for Hyponatremic Neuro-ICU Patients Terminated NCT00727090 Phase 4 Conivaptan
41 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
42 Post-approval Study of NovoTTF-100A in Recurrent GBM Patients Terminated NCT01756729 Phase 4
43 Genetically-informed Therapies for Patients With Metastatic Cancer Withdrawn NCT02000739 Phase 4
44 Efficacy of Tranexamic Acid in Brain Tumor Resections Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
45 Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children Unknown status NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;etoposide;trofosfamide/etoposide
46 SCRT Versus Conventional RT in Children and Young Adults With Low Grade and Benign Brain Tumors Unknown status NCT00517959 Phase 3
47 Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
48 Local Radiotherapy Following Complete Resection of a Brain Metastasis Unknown status NCT02729558 Phase 3
49 Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
50 Cognitive Rehabilitation of Glioma Patients Unknown status NCT00256425 Phase 3

Search NIH Clinical Center for Brain Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: brain neoplasms

Genetic Tests for Brain Cancer

Genetic tests related to Brain Cancer:

# Genetic test Affiliating Genes
1 Neoplasm of Brain 29
2 Malignant Neoplasm of Brain 29

Anatomical Context for Brain Cancer

MalaCards organs/tissues related to Brain Cancer:

41
Brain, Lung, Pituitary, Breast, T Cells, Testes, Bone

Publications for Brain Cancer

Articles related to Brain Cancer:

(show top 50) (show all 555)
# Title Authors Year
1
Perilesional edema in brain cancer: Independent prognosticator or epiphenomenon of biomolecular signature? ( 29331541 )
2018
2
Epstein-Barr virus- and cytomegalovirus-specific immune response in patients with brain cancer. ( 29970101 )
2018
3
A Repurposed Drug for Brain Cancer: Enhanced Atovaquone Amorphous Solid Dispersion by Combining a Spontaneously Emulsifying Component with a Polymer Carrier. ( 29783757 )
2018
4
Does Risk of Brain Cancer Increase with Intracranial Volume? A Population-Based Case-Control Study. ( 29554311 )
2018
5
Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules. ( 29603739 )
2018
6
Brain Cancer: Implication to Disease, Therapeutic Strategies and Tumor Targeted Drug Delivery Approaches. ( 29189177 )
2018
7
Brain-Resident Microglia and Blood-Borne Macrophages Orchestrate Central Nervous System Inflammation in Neurodegenerative Disorders and Brain Cancer. ( 29681904 )
2018
8
Spatio-spectral classification of hyperspectral images for brain cancer detection during surgical operations. ( 29554126 )
2018
9
Response to 'Perilesional edema in brain cancer: Independent prognosticator or epiphenomenon of biomolecular signature?' ( 29343408 )
2018
10
Heart Variability Biofeedback as Supplementary Care for Brain Cancer: A Feasibility Study. ( 29653058 )
2018
11
Development of core-shell nanocarrier system for augmenting piperine cytotoxic activity against human brain cancer cell line. ( 29597041 )
2018
12
Micro-imaging of Brain Cancer Radiation Therapy Using Phase-contrast Computed Tomography. ( 29976510 )
2018
13
Biofabrication of morphology improved cadmium sulfide nanoparticles using Shewanella oneidensis bacterial cells and ionic liquid: For toxicity against brain cancer cell lines. ( 29207279 )
2018
14
The role of income in brain tumor patients: a descriptive register-based study : No correlation between patients' income and development of brain cancer. ( 29532282 )
2018
15
Special Issue on Precision Medicine for Brain Cancer in ACS Chemical Neuroscience. ( 29338188 )
2018
16
Validation of the Chinese version of EORTC QLQ-BN20 for patients with brain cancer. ( 29461664 )
2018
17
Investigating the Ketogenic Diet As Treatment for Primary Aggressive Brain Cancer: Challenges and Lessons Learned. ( 29536011 )
2018
18
The biochemical, nanomechanical and chemometric signatures of brain cancer. ( 28688336 )
2018
19
Patients' experiences and care needs during the diagnostic phase of an integrated brain cancer pathway: A case study. ( 29603812 )
2018
20
Brain cancer genomics and epigenomics. ( 29478614 )
2018
21
Melatonin disturbs SUMOylation-mediated crosstalk between c-Myc and nestin via MT1 activation and promotes the sensitivity of paclitaxel in brain cancer stem cells. ( 29654697 )
2018
22
Curcumin-lipoic acid conjugate as a promising anticancer agent on the surface of golda89iron oxide nanocomposites: A pH-sensitive targeted drug delivery system for brain cancer theranostics. ( 29248558 )
2018
23
Enhanced Photogeneration of Reactive Oxygen Species and Targeted Photothermal Therapy of C6 Glioma Brain Cancer Cells by Folate-Conjugated Gold-Photoactive Polymer Nanoparticles. ( 29787247 )
2018
24
Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment. ( 29391205 )
2018
25
Brain Cancer Imaging Phenomics Toolkit (brain-CaPTk): An Interactive Platform for Quantitative Analysis of Glioblastoma. ( 29733087 )
2018
26
The Molecular Mechanisms of Plant-Derived Compounds Targeting Brain Cancer. ( 29385679 )
2018
27
Correction: SlicerDMRI: Open Source Diffusion MRI Software for Brain Cancer Research. ( 29716952 )
2018
28
Could a plant derived protein potentiate the anticancer effects of a stem cell in brain cancer? ( 29765540 )
2018
29
Inhibition of Translesion DNA Synthesis as a Novel Therapeutic Strategy to Treat Brain Cancer. ( 29259011 )
2018
30
Nanotheranostics: Emerging Strategies for Early Diagnosis and Therapy of Brain Cancer. ( 29291164 )
2018
31
A new method using Raman spectroscopy for in vivo targeted brain cancer tissue biopsy. ( 29379121 )
2018
32
Increased risk of brain cancer incidence in stroke patients: a clinical case series, population-based and longitudinal follow-up study. ( 29312585 )
2017
33
Towards carborane-functionalised structures for the treatment of brain cancer. ( 28886331 )
2017
34
Robust and fast characterization of OCT-based optical attenuation using a novel frequency-domain algorithm for brain cancer detection. ( 28327613 )
2017
35
Characterization of PTEN mutations in brain cancer reveals that pten mono-ubiquitination promotes protein stability and nuclear localization. ( 28263967 )
2017
36
Toxicity of Cisplatin-Loaded Poly Butyl Cyanoacrylate Nanoparticles in a Brain Cancer Cell Line: Anionic Polymerization Results ( 28440967 )
2017
37
Trends in brain cancer mortality among U.S. Gulf War veterans: 21 year follow-up. ( 28780478 )
2017
38
Combined Proteomic-Molecular Epidemiology Approach to Identify Precision Targets in Brain Cancer. ( 28657708 )
2017
39
Genetically engineered rat gliomas: PDGF-driven tumor initiation and progression in tv-a transgenic rats recreate key features of human brain cancer. ( 28358926 )
2017
40
Brain Cancer Stem Cells in Adults and Children: Cell Biology and Therapeutic Implications. ( 28374184 )
2017
41
Brain cancer therapy. ( 28104878 )
2017
42
Rethinking Brain Cancer Therapy: Tumor Enzyme Activatable Theranostic Nanoparticles. ( 28929923 )
2017
43
The views of patients with brain cancer about palliative care: a qualitative study. ( 29270049 )
2017
44
Metabolomic signature of brain cancer. ( 28618012 )
2017
45
Detecting and treating brain cancer. ( 28611178 )
2017
46
Radiochemical Evaluation and <i>In Vitro</i> Assessment of the Targeting Ability of a Novel <sup>99m</sup>Tc-HYNIC-RGD for U87MG Human Brain Cancer Cells. ( 28681701 )
2017
47
Risk of severe acute liver injury among patients with brain cancer treated with temozolomide: a nested case-control study using the healthcore integrated research database. ( 28717885 )
2017
48
Brain cancer: Temozolomide improves outcomes. ( 28857072 )
2017
49
British-led research uncovers new details on brain cancer. ( 28421936 )
2017
50
Is myelin basic protein a potential biomarker of brain cancer? ( 29028399 )
2017